(AUDIO) Dr. Mark Shlomchik has won the first $200,000 Insight Prize for research that led toward new lupus drugs such as belimumab. In a brief recorded interview, hear how the award may help him find an explanation for the links between infection and lupus. More »
Some patients with systemic lupus erythematosus or antiphospholipid syndrome may initially present with movement disorders, especially chorea. Physicians may not associate these symptoms with either disorder, thereby delaying diagnosis and effective treatment. More »
The latest results from two late-stage, multicenter clinical trials of belimumab (Benlysta) show that, when given alongside standard therapy for systemic lupus erythematosus, the drug improves health-related quality of life (HRQOL) and fatigue. More »
SLE is associated with a deficiency in cluster of differentiation 247 (CD247, also known as CD3 zeta chain), a component of the T-cell receptor (TCR)–CD3 complex. A comprehensive analysis showed that in more than half of SLE patients tested CD247 expression was either attenuated or absent. Recent evidence suggests that these variations in expression profiles may be due, at least in part, to polymorphisms in the CD247 gene. Aberrant CD247 transcript variants displaying either spliced
Assess the effects of belimumab treatment plus standard systemic lupus erythematosus (SLE) therapy on health-related quality of life (HRQOL) in patients with active, autoantibody-positive SLE.
Patients received standard therapy plus placebo or belimumab 1 or 10 mg/kg in two multicentre, randomised controlled trials of 52 (BLISS-52; N=865) and 76 (BLISS-76; N=819) weeks’ duration. Responders were evaluated by SLE Responder Index at week
Objective. A review of the literature was undertaken to evaluate the development and psychometric properties of health-related quality of life (HRQoL) measures used in adults with SLE. This information will help clinicians make an informed choice about the measures most appropriate for research and clinical practice.
Methods. Using the key words lupus and quality of life, full original papers in English were identified from six databases: OVID MEDLINE, EMBASE, Allied and Complemen
Pathogenic IgG autoantibodies have established roles in diseases including systemic lupus erythematosus and rheumatoid arthritis. Less familiar are the influences of naturally arising IgM autoantibodies, which enhance phagocytic clearance of apoptotic cells and have the capacity to block inflammatory responses induced by Toll-like receptor ligands and autoantibody-containing immune complexes. Intriguing data from animal models and clinical studies, suggesting that it might become possible to exploit these